Role of Liver X Receptor in AD Pathophysiology

Alzheimer's disease (AD) is the major cause of dementia worldwide. The pharmacological activation of nuclear receptors (Liver X receptors: LXRs or Retinoid X receptors: RXR) has been shown to induce overexpression of the ATP-Binding Cassette A1 (ABCA1) and Apolipoprotein E (ApoE), changes that...

Full description

Autores:
Cardona Gómez, Gloria Patricia
Sandoval Hernández, Adrián G.
Buitrago, Luna
Moreno, Herman
Arboleda Bustos, Gonzalo
Tipo de recurso:
Article of investigation
Fecha de publicación:
2015
Institución:
Universidad de Antioquia
Repositorio:
Repositorio UdeA
Idioma:
eng
OAI Identifier:
oai:bibliotecadigital.udea.edu.co:10495/47824
Acceso en línea:
https://hdl.handle.net/10495/47824
Palabra clave:
610 - Medicina y salud
Transportador 1 de Casete de Unión a ATP
ATP Binding Cassette Transporter 1
Alzheimer Disease
Enfermedad de Alzheimer
Péptidos beta-Amiloides
Amyloid beta-Peptides
Apolipoproteínas E
Apolipoproteins E
Benzoatos
Benzoates
Bencilaminas
Benzylamines
Corteza Cerebral
Cerebral Cortex
Trastornos del Conocimiento
Cognition Disorders
Proteínas de Unión al ADN
DNA-Binding Proteins
Giro Dentado
Dentate Gyrus
Hipocampo
Hippocampus
Receptores X del Hígado
Liver X Receptors
https://id.nlm.nih.gov/mesh/D064286
https://id.nlm.nih.gov/mesh/D000544
https://id.nlm.nih.gov/mesh/D016229
https://id.nlm.nih.gov/mesh/D001057
https://id.nlm.nih.gov/mesh/D001565
https://id.nlm.nih.gov/mesh/D001596
https://id.nlm.nih.gov/mesh/D002540
https://id.nlm.nih.gov/mesh/D003072
https://id.nlm.nih.gov/mesh/D004268
https://id.nlm.nih.gov/mesh/D018891
https://id.nlm.nih.gov/mesh/D006624
https://id.nlm.nih.gov/mesh/D000071518
ODS 3: Salud y bienestar. Garantizar una vida sana y promover el bienestar de todos a todas las edades
Rights
openAccess
License
http://creativecommons.org/licenses/by/4.0/
Description
Summary:Alzheimer's disease (AD) is the major cause of dementia worldwide. The pharmacological activation of nuclear receptors (Liver X receptors: LXRs or Retinoid X receptors: RXR) has been shown to induce overexpression of the ATP-Binding Cassette A1 (ABCA1) and Apolipoprotein E (ApoE), changes that are associated with improvement in cognition and reduction of amyloid beta pathology in amyloidogenic AD mouse models (i.e. APP, PS1: 2tg-AD). Here we investigated whether treatment with a specific LXR agonist has a measurable impact on the cognitive impairment in an amyloid and Tau AD mouse model (3xTg-AD: 12-months-old; three months treatment). The data suggests that the LXR agonist GW3965 is associated with increased expression of ApoE and ABCA1 in the hippocampus and cerebral cortex without a detectable reduction of the amyloid load. We also report that most cells overexpressing ApoE (86±12%) are neurons localized in the granular cell layer of the hippocampus and entorhinal cortex. In the GW3965 treated 3xTg-AD mice we also observed reduction in astrogliosis and increased number of stem and proliferating cells in the subgranular zone of the dentate gyrus. Additionally, we show that GW3965 rescued hippocampus long term synaptic plasticity, which had been disrupted by oligomeric amyloid beta peptides. The effect of GW3965 on synaptic function was protein synthesis dependent. Our findings identify alternative functional/molecular mechanisms by which LXR agonists may exert their potential benefits as a therapeutic strategy against AD.